Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18808320 | 0.83 | TP53 (0.49) | TSHRCYP3A4HIF1AALDH1A1TP53 | |
| SCHEMBL6781013 | 0.83 | ROR1 (0.39) | TSHRCYP3A4HIF1AALDH1A1TP53 | |
| SCHEMBL6317619 | 0.82 | TSHR (0.44) | TSHRCYP3A4HIF1AALDH1A1TP53 | |
| SCHEMBL6493903 | 0.81 | HTR2C (0.54) | TSHRHTR2CHTR2AHTR2BPARP1 | |
| SCHEMBL936624 | 0.81 | HTR2C (0.54) | TSHRHTR2CHTR2AHTR2BPARP1 | |
| SCHEMBL7784267 | 0.81 | HTR2C (0.54) | TSHRHTR2CHTR2AHTR2BPARP1 | |
| SCHEMBL8303700 | 0.80 | ALDH1A1 (0.40) | TSHRCYP3A4HIF1AALDH1A1TP53 | |
| SCHEMBL767828 | 0.77 | CYP3A4 (0.39) | TSHRCYP3A4HIF1AALDH1A1TP53 | |
| SCHEMBL10434809 | 0.77 | HTR2C (0.50) | HTR2CADRA1AHTR1AADRA1DDRD2 | |
| SCHEMBL1607526 | 0.76 | MAOB (0.48) | TSHRCYP3A4HIF1AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7745665-B2 | Substituted phenethylamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745665-B2 | Substituted phenethylamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745665-B2 | Substituted phenethylamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2008151179-A2 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151179-A2 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | ADRB1, ADRB2, ADRA1A | TSHR 1260/4885CYP3A4 774/4885HIF1A 86/4885 |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | ADRB1, ADRA2C, ADRB2 | TSHR 620/4885CYP3A4 98/4885HIF1A 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.